{"disease":{"id":"mpn-myeloproliferative-neoplasms","name":"mpn myeloproliferative neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT02252159","title":"Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)","phase":"","overall_status":"COMPLETED","enrollment_count":2544,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT02953704","title":"Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)","phase":"","overall_status":"COMPLETED","enrollment_count":1469,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT01633372","title":"An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT02718300","title":"A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT01348490","title":"Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03011372","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03144687","title":"A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03123588","title":"Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Incyte Corporation","has_results":true}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}